Compare Quest Diagnostics Inc (DGX) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Invesco Solar ETF — how do they compare? Quest Diagnostics Inc trades at $230.32 (market cap $25.48B), while Invesco Solar ETF trades at $43.55 (market cap $894.08M). The key difference: Quest Diagnostics Inc is far larger — about 28.5× Invesco Solar ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Invesco Solar ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Invesco Solar ETF for 34 Days on average.
| DGX | TAN | |
|---|---|---|
Market Cap | $25.48B | $894.08M |
Volume | 941,866 | 370,994 |
Sector | Health | Sector/Thematic |
52-Week High | $247.45 | $73.95 |
52-Week Low | $173.49 | $43.00 |
Typical Hold Time | 56 Days | 34 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
TAN (Invesco Solar ETF) is trading at $43.53, down 1.96% amid sector-wide pressure from high borrowing costs impacting solar project financing. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from solar industry volatility, price deflation, and margin erosion, having underperformed the S&P 500 by 112% over five years according to Seeking Alpha analysis from August 2026.
Outlook remains challenging with persistent sector headwinds including interest rate sensitivity and market saturation risks. Investment opportunity exists in long-term renewable energy transition, but requires tolerance for high volatility and deeper drawdowns compared to traditional energy ETFs. Key risks include policy uncertainty, grid adaptation costs, and competitive pressure from broader clean energy alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
